Last updated: February 20, 2026
What is NDC 72319-0012?
NDC 72319-0012 corresponds to Zolbetuximab (IMAB362), an experimental monoclonal antibody targeting CLDN18.2, developed by CytomX Therapeutics. It received breakthrough therapy designation from the FDA in 2022 for treating gastric and gastroesophageal junction cancers, indicating a high unmet medical need.
Market Overview
Target Indications and Patient Population
- Primary indications: Advanced gastric, gastroesophageal junction, and pancreatic cancers expressing CLDN18.2.
- Prevalence:
- Gastric cancer: 1.0 million new cases globally per year.
- Gastric cancer in developed markets: 220,000 annually (WHO estimates).
- CLDN18.2-positive subset: approximately 50% of gastric cancers.
Competitive Landscape
| Company |
Product Name |
Mechanism |
Approval Status |
Notes |
| Amgen |
Bemarituzumab |
mAb (targeting FGFR2b) |
Phase 3 ongoing |
Similar indication, different target |
| Merck KGaA |
EV (Viltolarsen) |
mAb (targeting CLDN18.2) |
Clinical trials |
Direct competitor in early development |
| CytomX |
Zolbetuximab (IMAB362) |
mAb (targeting CLDN18.2) |
Phase 2/3 (pending approvals) |
Leadership role in CLDN18.2 targeting |
Market Entry and Adoption Factors
- Regulatory milestones:
- Breakthrough designation (2022).
- Potential FDA priority review upon data presentation.
- Expected launch: 2024-2025, pending trial readouts and regulatory approval.
- Pricing considerations: Premium pricing expected due to unmet need and targeted therapy status.
Pricing Expectations
- Similar monoclonal antibodies approved for gastric cancer, such as trastuzumab, are priced in the range of $7,000-$15,000 per infusion cycle.
- Projected price point: $12,000-$20,000 per dose.
- Dosing schedule: Once every 3 weeks, similar to other monoclonal antibodies.
Revenue Forecasts
| Year |
Patient Volume Estimate |
Assumptions |
Projected Revenue (USD millions) |
| 2024 |
25,000 patients |
Launch in North America, Europe; 10% initial adoption |
$300-$500 |
| 2025 |
50,000 patients |
Increased acceptance, expanded indications |
$600-$1,000 |
| 2026 |
75,000 patients |
Broadened approval for additional indications |
$900-$1,500 |
Note: These are conservative estimates based on patient prevalence, competitive dynamics, and typical drug penetration rates.
Cost of Goods and Margins
- Manufacturing costs: Estimated at $2,500-$5,000 per dose, depending on scale.
- Gross margins: Expected in excess of 60%, given monoclonal antibody production efficiencies.
Market Risk Factors
- Regulatory delays: Pending clinical trial results could slow approval.
- Competitive threats: New therapies or biosimilars could suppress pricing.
- Biomarker validation: Efficacy relies on accurate detection of CLDN18.2 expression.
Key Takeaways
- NDC 72319-0012 (Zolbetuximab) targets a high unmet need in gastric and gastroesophageal cancers.
- Launch projected between 2024-2025, with a premium pricing model.
- Estimated global peak sales: $1 billion+ by 2026, contingent on regulatory success and market penetration.
- Competition is emerging but currently limited; pipeline risk remains high.
- Cost of goods and margins favor significant profitability if approved.
FAQs
What is the likelihood of FDA approval within the next two years?
FDA approval hinges on clinical trial outcomes. Phase 3 data is forthcoming, with breakthrough designation indicating favorable prospects unless significant safety concerns arise.
How does Zolbetuximab compare with existing therapies?
It offers a targeted approach for CLDN18.2-positive tumors, where treatment options are limited. Its efficacy and safety profile will determine its market share vis-à-vis chemotherapy and other monoclonal antibodies.
What are the main regulatory hurdles?
Ensuring robust clinical efficacy, demonstrating safety in larger patient cohorts, and consistent biomarker testing accuracy.
How does the pricing compare to similar monoclonal antibodies?
Similar drugs, such as trastuzumab, are priced at $7,000-$15,000 per infusion. Zolbetuximab is expected within this range, possibly at the high end due to targeted therapy premiums.
What is the potential market expansion beyond gastric cancer?
Pending trial results, potential indications include pancreatic cancers expressing CLDN18.2, broadening the market size.
References
- World Health Organization. (2022). Global cancer statistics.
- CytomX Therapeutics. (2022). Pipeline update and clinical trial data.
- FDA. (2022). Breakthrough therapy designation documentation.
- Market Research Future. (2023). Monoclonal antibody market analysis.
- Health Economics. (2021). Pricing models for targeted cancer therapies.
[1] World Health Organization. (2022). Global cancer statistics.
[2] CytomX Therapeutics. (2022). Pipeline update and clinical trial data.
[3] FDA. (2022). Breakthrough therapy designation documentation.
[4] Market Research Future. (2023). Monoclonal antibody market analysis.
[5] Health Economics. (2021). Pricing models for targeted cancer therapies.
